Omeros Corporation (0KBU.L)
| Previous close | 3.9200 |
| Open | 3.7700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.7700 - 3.8982 |
| 52-week range | 0.9901 - 7.7838 |
| Volume | |
| Avg. volume | 2,368 |
| Market cap | 170.666M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | 0.01 |
| EPS (TTM) | 3.1390 |
| Earnings date | 07 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Retail investors account for 52% of Omeros Corporation's (NASDAQ:OMER) ownership, while institutions account for 43%
Key Insights Omeros' significant retail investors ownership suggests that the key decisions are influenced by...
- Associated Press Finance
Omeros: Q2 Earnings Snapshot
SEATTLE (AP) — Omeros Corporation OMER on Wednesday reported a loss of $56 million in its second quarter. On a per-share basis, the Seattle-based company said it had a loss of 97 cents. Losses, adjusted to account for discontinued operations, were $1.12 per share.
Business WireOmeros Corporation Reports Second Quarter 2024 Financial Results
SEATTLE, August 07, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2024, whic
